Colleen Acosta, Freya Biosciences CEO

Ex­clu­sive: Women’s health biotech Freya Bio­sciences rais­es $38M for mi­cro­bial im­munother­a­pies

Freya Bio­sciences, a Dan­ish and US biotech named af­ter the Norse god­dess of fer­til­i­ty, has raised a $38 mil­lion Se­ries A, the clin­i­cal-stage start­up told End­points News ex­clu­sive­ly.

The Copen­hagen and Boston start­up, formed dur­ing the ear­ly days of the Covid-19 pan­dem­ic, will use the fund­ing to test its in­ves­ti­ga­tion­al donor- and strain-de­rived mi­cro­bial im­munother­a­pies.

“If we can shift the mi­cro­bial ecol­o­gy, we have that cor­re­spond­ing shift in the im­mune pro­file, which would then have an ef­fect on these quite se­vere in­di­ca­tions that are down­stream of this in­flam­ma­tion that aris­es in the re­pro­duc­tive tract,” CEO Colleen Acos­ta said in an in­ter­view with End­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA